# A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

> **NCT02332824** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 415 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus and Microalbuminuria

## Interventions

- **DRUG:** TAK-272
- **DRUG:** TAK-272 Placebo
- **DRUG:** Candesartan cilexetil
- **DRUG:** Candesartan cilexetil Placebo

## Key facts

- **NCT ID:** NCT02332824
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-16
- **Primary completion:** 2016-08-18
- **Final completion:** 2016-08-18
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332824, "A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02332824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*